Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Nidanilimab

Copy Product Info
😃Good
Catalog No. T76873Cas No. 2171061-85-9
Alias Nadunolimab, CAN04

Nidanilimab (CAN04) is a fully humanized IL1RAP monoclonal antibody with a Kd value of 1.10 pM. It exhibits antitumor activity by disrupting the IL1α and IL1β signaling pathways and inducing the immune system to destroy tumor cells. Nidanilimab can be used to study solid cancers, such as non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC).

Nidanilimab

Nidanilimab

Copy Product Info
😃Good
Catalog No. T76873Alias Nadunolimab, CAN04Cas No. 2171061-85-9
Nidanilimab (CAN04) is a fully humanized IL1RAP monoclonal antibody with a Kd value of 1.10 pM. It exhibits antitumor activity by disrupting the IL1α and IL1β signaling pathways and inducing the immune system to destroy tumor cells. Nidanilimab can be used to study solid cancers, such as non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC).
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$243In StockIn Stock
5 mg$753In StockIn Stock
10 mg$1,180-In Stock
25 mg$1,750-In Stock
50 mg$2,350-In Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:> 95%
Appearance:Liquid
Color:Transparent
Contact us for more batch information

Product Introduction

Bioactivity
Description
Nidanilimab (CAN04) is a fully humanized IL1RAP monoclonal antibody with a Kd value of 1.10 pM. It exhibits antitumor activity by disrupting the IL1α and IL1β signaling pathways and inducing the immune system to destroy tumor cells. Nidanilimab can be used to study solid cancers, such as non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC).
Targets&IC50
MC38 colon cancer cells (mouse):1 nM(EC50)
In vitro
Nidanilimab (CAN04; 20 µg/mL) exhibits antibody-dependent cell-mediated cytotoxicity (ADCC) with glycoengineering-enhanced properties in mouse MC38 colon cancer cells, with an EC50 of less than 1 nM[2]. Nidanilimab (20 µg/mL) blocks the IL1α and IL1β signaling pathways in mouse MC38 colon cancer cells, with IC50 values of 3.9 nM and 4.1 nM, respectively[2].
In vivo
In nude C57Bl/6 mice, Nidanilimab (CAN04; 10 mg/kg; intraperitoneal injection) enhances the efficacy of two commonly used platinum-based chemotherapy drugs, cisplatin with gemcitabine and carboplatin with gemcitabine[1].
SynonymsNadunolimab, CAN04
Reactivity
Human
Verified Activity
Immobilized Human IL-1RAP/IL-1R3 Protein (Fc) at 2 μg/mL (30 μL/well) can bind Nidanilimab. The EC50 is 19.97 ng/mL.
verifiedActivity
Application
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
Gene ID
Uniprot ID
TargetIL-1RAP/IL-1R3
Chemical Properties
Molecular Weight150 kDa
Cas No.2171061-85-9
Antibody Information
IsotypeHuman IgG1 kappa
Recommended Isotype Control
Storage & Solubility Information
Storagestore at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator

Keywords

Related Tags: buy Nidanilimab | purchase Nidanilimab | Nidanilimab cost | order Nidanilimab | Nidanilimab in vivo | Nidanilimab in vitro | Nidanilimab molecular weight